HCWB
HCW Biologics Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.87
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 6.7M | 54.2K | 2.6M | 2.8M | 6.7M |
| Cost of Revenue | 274.6K | 43.4K | 1.6M | 2.3M | 4.1M |
| Gross Profit | 6.4M | 10.8K | 959.4K | 560.4K | 2.6M |
| Operating Expenses | |||||
| R&D Expense | 5.2M | 5.4M | 6.4M | 7.7M | 9.3M |
| SG&A Expense | 7.1M | 7.7M | 21.9M | 13.1M | 8.0M |
| General & Admin Expense | 7.1M | 7.7M | 21.9M | 13.1M | 8.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 323.6K | (1.9M) | 2.1M | 5.5M | 338.5K |
| Total Operating Expenses | 12.6M | 11.3M | 30.4M | 26.3M | 17.7M |
| Cost and Expenses | 12.9M | 11.3M | 32.0M | 28.6M | 21.8M |
| Operating Income (EBIT) | (6.2M) | (11.3M) | (29.5M) | (25.7M) | (15.1M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 360.4K | 1.3M | 1.2M | 283.0K | 126.7K |
| Net Interest Income | (360.4K) | (1.3M) | (1.2M) | (283.0K) | (126.7K) |
| Other Non-Op Income/Expense | 922.2K | 3.3M | (544.1K) | 722.9K | 178.1K |
| Non-Operating Income (excl Interest) | (1.3M) | (4.5M) | (614.3K) | (1.0M) | (304.7K) |
| EBT (Pre-Tax Income) | (5.2M) | (8.0M) | (30.0M) | (25.0M) | (14.9M) |
| Income Tax Expense | (330.2K) | — | — | — | — |
| Bottom Line | |||||
| Net Income | (4.9M) | (8.0M) | (30.0M) | (25.0M) | (14.9M) |
| Earnings from Cont. Ops | (4.9M) | (8.0M) | (30.0M) | (25.0M) | (14.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (19.3M) | (22.3M) | (30.0M) | (25.0M) | (14.9M) |
| Per Share | |||||
| Basic EPS | ($54.17) | ($63.78) | ($4.62) | ($4.20) | ($2.52) |
| Diluted EPS | ($54.17) | ($63.78) | ($4.62) | ($4.20) | ($2.52) |
| Revenue Per Share | $19.22 | $0.16 | $0.40 | $0.47 | $1.13 |
| Shares | |||||
| Basic Shares Outstanding | 349617 | 349617 | 6.5M | 6.0M | 6.0M |
| Diluted Shares Outstanding | 349617 | 349617 | 6.5M | 6.0M | 6.0M |
| Profitability Metrics | |||||
| EBITDA | (4.3M) | (5.7M) | (27.7M) | (23.6M) | (14.1M) |
| D&A | 600.0K | 1.0M | 1.2M | 1.1M | 717.9K |
| EBIT | (4.9M) | (6.7M) | (28.9M) | (24.7M) | (14.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026